Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Uterine Leiomyosarcoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Uterine Leiomyosarcoma	No biomarker	Uterine Leiomyosarcoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
ER positive	Uterine Leiomyosarcoma	ER positive	Uterine Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
PGR positive	Uterine Leiomyosarcoma	PGR positive	Uterine Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
PGR positive	Uterine Leiomyosarcoma	PGR positive	Uterine Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
ER positive	Uterine Leiomyosarcoma	ER positive	Uterine Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
PGR positive	Uterine Leiomyosarcoma	PGR positive	Uterine Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
ER positive	Uterine Leiomyosarcoma	ER positive	Uterine Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
AKT1 E17K	Uterine Leiomyosarcoma	AKT1 E17K	Uterine Leiomyosarcoma	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
CD70 expression	Uterine Leiomyosarcoma	CD70 expression	Uterine Leiomyosarcoma	JNJ-0631 Sensitive: C3 – Early Trials JNJ-0631 Sensitive : C3	JNJ-0631 Sensitive: C3 – Early Trials JNJ-0631 Sensitive : C3
ER positive + PGR positive	Uterine Leiomyosarcoma	ER positive + PGR positive	Uterine Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
PGR positive	Uterine Leiomyosarcoma	PGR positive	Uterine Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
ER positive	Uterine Leiomyosarcoma	ER positive	Uterine Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3